News and Announcements
Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked.
Phosphatidylinositol 3-kinase inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). While patients may show an initial response to these therapies, development of treatment intolerance or resistance remains clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of ten PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki.
Check out this great collection of Precision Medicine and Therapeutic Research curated by Cancer Discovery editors selected from the Journal. Some of these select original research articles are followed by their corresponding In the Spotlight commentaries, which serve to place them in the context of their field
This February 2020 issue of Cancer Discovery features reports of two very important prospective clinical trials from SFPM members in Zurich, Vienna, Stockholm and Helsinki. Both studies demonstrate the feasibility and utility of functional precision medicine tools in the clinical oncology setting. A commentary by Tony Letai accompanies these articles.
This February 2020 issue of Cancer Discovery features reports of two very important prospective clinical trials from SFPM members in Zurich, Vienna, Stockholm and Helsinki. Both studies demonstrate the feasibility and utility of functional precision medicine tools in the clinical oncology setting. A commentary by Tony Letai accompanies these articles.
This February 2020 issue of Cancer Discovery features reports of two very important prospective clinical trials from SFPM members in Zurich, Vienna, Stockholm and Helsinki. Both studies demonstrate the feasibility and utility of functional precision medicine tools in the clinical oncology setting. A commentary by Tony Letai accompanies these articles.
IN 2018, SfPM Member Alana Welm found herself in an exciting, yet burdensome, position. The University of Utah breast cancer research lab where she leads joint projects with her husband, Bryan Welm, had created lab-grown versions of real tumors isolated from living cancer patients. Each cancer had been translated into two kinds of biological models: xenografts, made by implanting tissue into mice, and organoids, miniature clumps of tissue grown in plastic dishes.
The Azzam Lab at Florida International University collaborates with clinicians at Nicklaus Children’s Hospital to guide therapeutic decisions for a 7-year old patient with metastatic refractory rhabdomyosarcoma using a personalized functional precision oncology approach. Their guided treatment plan led to longer progression-free survival than the regimen on which the patient had just experienced progression. This report is the first demonstration of the efficacy of functional precision medicine in guiding treatments in children.
Researchers at MIT and Dana-Farber Cancer Institute have developed a high-throughput assay that detects subtle changes in the mass of individual drug-treated cancer cells as a surrogate biomarker for patient treatment response. Their findings suggest cell mass is a promising functional biomarker for cancers and drugs that lack genomic biomarkers.
We would like to invite you to a webinar co-hosted by Oncology Convention Expo, Precision Oncology: Beyond Biomarkers on 5th October at 14:00 (BST).
Sanford M. Simon and his group tested over 5,000 compounds, either already approved for other clinical uses or in clinical trials, to see whether any of the compounds could be repurposed to treat fibrolamellar. The team used PDX models to uncover a few classes of therapeutics that eliminate fibrolamellar tumor cells grown in mice.